FAQ/Help |
Calendar |
Search |
Today's Posts |
|
12-18-2021, 10:27 PM | #1 | ||
|
|||
Member
|
"The failure of Nilotinib to provide a clinically meaningful benefit in PD patients in two double-blind studies is discouraging, but may be explained by the fact that nilotinib does not accumulate in the brain at concentrations sufficient to inhibit c-Abl."
https://movementdisorders.onlinelibr...1002/mds.28858 |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
2019 Nilotinib status | Parkinson's Disease | |||
Nilotinib 2018 | Parkinson's Disease | |||
Frustrated on priority with Tasigna/nilotinib | Parkinson's Disease | |||
Tasigna: would you do it? | Parkinson's Disease |